Brookstone Capital Management Grows Stock Position in Thermo Fisher Scientific Inc. (NYSE:TMO)

Brookstone Capital Management increased its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 248.8% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 8,128 shares of the medical research company's stock after buying an additional 5,798 shares during the period. Brookstone Capital Management's holdings in Thermo Fisher Scientific were worth $4,045,000 as of its most recent SEC filing.

A number of other large investors have also recently made changes to their positions in the stock. Bernard Wealth Management Corp. purchased a new stake in Thermo Fisher Scientific in the 4th quarter worth approximately $25,000. Pillar Financial Advisors LLC purchased a new stake in shares of Thermo Fisher Scientific in the fourth quarter worth $29,000. Ameriflex Group Inc. bought a new stake in Thermo Fisher Scientific during the fourth quarter valued at $30,000. Cassady Schiller Wealth Management LLC increased its stake in Thermo Fisher Scientific by 89.2% in the 4th quarter. Cassady Schiller Wealth Management LLC now owns 70 shares of the medical research company's stock worth $36,000 after acquiring an additional 33 shares during the last quarter. Finally, VSM Wealth Advisory LLC bought a new stake in shares of Thermo Fisher Scientific during the 4th quarter valued at about $36,000. 89.23% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of equities analysts have recently commented on TMO shares. Evercore ISI decreased their price target on shares of Thermo Fisher Scientific from $585.00 to $500.00 and set an "outperform" rating on the stock in a report on Thursday, April 24th. Argus lowered their price target on Thermo Fisher Scientific from $620.00 to $470.00 and set a "buy" rating on the stock in a research report on Tuesday, April 29th. Wells Fargo & Company reduced their price objective on Thermo Fisher Scientific from $580.00 to $570.00 and set an "overweight" rating on the stock in a research report on Thursday, April 24th. UBS Group dropped their target price on Thermo Fisher Scientific from $715.00 to $500.00 and set a "buy" rating for the company in a research report on Thursday, April 24th. Finally, Royal Bank Of Canada cut their price objective on shares of Thermo Fisher Scientific from $651.00 to $637.00 and set an "outperform" rating for the company in a research note on Thursday, April 24th. Four research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $604.05.

Insiders Place Their Bets

In related news, EVP Gianluca Pettiti sold 300 shares of the company's stock in a transaction that occurred on Monday, April 28th. The stock was sold at an average price of $429.93, for a total value of $128,979.00. Following the transaction, the executive vice president directly owned 23,167 shares of the company's stock, valued at approximately $9,960,188.31. This represents a 1.28% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Corporate insiders own 0.33% of the company's stock.

Thermo Fisher Scientific Trading Down 2.5%

Shares of NYSE:TMO traded down $10.57 on Monday, hitting $418.76. The company had a trading volume of 2,497,096 shares, compared to its average volume of 1,976,560. The firm has a market capitalization of $158.08 billion, a price-to-earnings ratio of 24.56, a P/E/G ratio of 2.28 and a beta of 0.77. The company has a quick ratio of 1.38, a current ratio of 1.77 and a debt-to-equity ratio of 0.64. The firm's 50-day simple moving average is $409.18 and its two-hundred day simple moving average is $479.39. Thermo Fisher Scientific Inc. has a 1 year low of $385.46 and a 1 year high of $627.88.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its quarterly earnings data on Wednesday, April 23rd. The medical research company reported $5.15 earnings per share for the quarter, topping analysts' consensus estimates of $5.10 by $0.05. Thermo Fisher Scientific had a net margin of 15.19% and a return on equity of 17.15%. The business had revenue of $10.36 billion for the quarter, compared to analysts' expectations of $10.23 billion. During the same quarter in the prior year, the company earned $5.11 earnings per share. The business's revenue was up .2% compared to the same quarter last year. Equities analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, July 15th. Stockholders of record on Friday, June 13th will be given a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 0.41%. The ex-dividend date is Friday, June 13th. Thermo Fisher Scientific's dividend payout ratio is presently 10.09%.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.